Products
Platform
Research
Market
Learn
Compare Bandhan Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | - | 1.87 |
NAV | ₹10.00 | ₹40.14 |
Fund Started | 10 Nov 2025 | 25 Jun 2018 |
Fund Size | - | ₹6437.36 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
-
1.87
NAV
₹10.00
₹40.14
Fund Started
10 Nov 2025
25 Jun 2018
Fund Size
-
₹6437.36 Cr
Exit Load
Exit load of 0.50%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | - | 3.67% |
3 Year | - | 27.07% |
5 Year | - | 21.12% |
1 Year
-
3.67%
3 Year
-
27.07%
5 Year
-
21.12%
Holding Analysis
Equity | 0.00% | 97.10% |
Cash | 0.00% | 2.90% |
Equity
0.00%
97.10%
Cash
0.00%
2.90%
Top Holdings
Top 10 Holdings | - |
|
Top 10 Holdings
-
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Fund Manager
Name | Viraj Kulkarni | Dharmesh Kakkad |
Start Date | 10 Nov 2025 | 23 Feb 2021 |
Name
Viraj Kulkarni
Dharmesh Kakkad
Start Date
10 Nov 2025
23 Feb 2021
About Fund
Description | The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 Nov 2025 | 25 Jun 2018 |
Description
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of companies engaged in Healthcare, Pharma and Allied sectors.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 Nov 2025
25 Jun 2018